Laverdia Tablets

How to Order Prescriptions

---

Description

LAVERDIA® (verdinexor tablets) is a prescription oral anticancer medication indicated for the treatment of lymphoma in dogs. It belongs to a class of medications known as selective inhibitors of nuclear export (SINE), which work by targeting proteins involved in tumor cell survival. LAVERDIA® is designed to selectively affect cancer cells while helping preserve normal cells.

Available in four tablet strengths, LAVERDIA® is administered twice weekly with food using a veterinarian-prescribed dosing schedule. Treatment should always be supervised by a veterinarian experienced in cancer therapy and requires routine monitoring for adverse effects and laboratory abnormalities.

Uses & Benefits

• FDA-approved for the treatment of lymphoma in dogs
• Oral alternative to injectable chemotherapy protocols
• Targets cancer cells through selective inhibition of nuclear export
• Convenient twice-weekly dosing schedule
• Available in multiple tablet strengths for individualized treatment
• May provide longer time to disease progression compared to placebo
• Can be used in both treatment-naïve and relapsed lymphoma patients under veterinary supervision

How It Works

Verdinexor is a selective inhibitor of nuclear export (SINE) that blocks exportin 1 (XPO1/CRM1). By preventing the export of tumor suppressor proteins and growth regulatory proteins from the nucleus, these proteins remain where they can perform their normal functions. This results in selective toxicity toward cancer cells with genomic damage while minimizing effects on healthy cells.

Indications

LAVERDIA® is indicated for:

• Treatment of lymphoma in dogs
• Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Ingredients

Active Ingredients:

Verdinexor

Inactive Ingredients:

Refer to the manufacturer's package insert for the complete inactive ingredient list.

Directions

• Feed your dog immediately before administering LAVERDIA®.
• Wear disposable chemotherapy-resistant gloves when handling tablets.
• Administer orally twice weekly with at least 72 hours between doses.
• Initial dose: 1.25 mg/kg twice weekly.
• After two weeks (if tolerated with  veterinarian approval): 1.5 mg/kg orally twice weekly
• Minimum adjusted dose: 1 mg/kg twice weekly if adverse reactions require dose reduction
• If tolerated after two weeks, the may increase the dose to 1.5 mg/kg twice weekly.
• Dose reductions or temporary treatment interruptions may be necessary if adverse reactions occur.
• Do not split, crush, or break tablets.

Your veterinarian will determine the proper combination of tablet strengths needed for each dose.

Cautions

• Federal law restricts this drug to use by or on the order of a licensed veterinarian.
• For oral use in dogs only.
• Not for use in humans.
• Do not split or crush tablets.
• Safe use has not been established in dogs younger than 7 months.
• Use has not been evaluated in dogs with significant renal, hepatic, cardiovascular disease, diabetes mellitus, hypercalcemia, or concurrent malignancies.
• Do not administer with drugs that undergo significant glutathione conjugation (such as acetaminophen) unless directed by your veterinarian.

Possible Side Effects

The most commonly reported adverse reactions include:
Decreased appetite (anorexia) / Vomiting / Lethargy / Weight loss / Diarrhea / Increased thirst / Increased urination / Fever / Muscle tremors / Muscle weakness / Eye redness or discharge / Ataxia / Elevated liver enzymes / Anemia / Thrombocytopenia / Elevated kidney values (BUN/Creatinine)

Serious adverse events, including death, have been reported. Contact your veterinarian immediately if your dog develops severe vomiting, diarrhea, weakness, collapse, bleeding, or refuses food.

Precautions

Treatment should be supervised by a veterinarian experienced in oncology.
Routine blood work is recommended during treatment to monitor hematologic and serum chemistry changes.
Appetite stimulants, anti-nausea medications, and prednisone may be prescribed to help manage gastrointestinal side effects.
Do not use in pregnant, breeding, or lactating dogs.
The medication may affect fertility in both males and females.
Keep tablets securely stored away from other animals to prevent accidental ingestion.

Storage

Store at 68°F to 77°F (20°C to 25°C). Keep bottles tightly closed with the desiccant inside. Store away from food, food preparation areas, and human medications. Keep out of reach of children and animals.

Disposal:

Dispose of unused tablets and waste materials according to procedures for cytotoxic (chemotherapy) drugs.

Wear chemotherapy-resistant gloves when handling tablets, waste, feces, urine, vomit, or saliva during treatment and for 3 days after the final dose.
Place contaminated waste in a sealed plastic bag before disposal.